General
Preferred name
SB 215505
Synonyms
SB215505 ()
SB-215505 ()
P&D ID
PD048953
CAS
162100-15-4
Tags
available
drug candidate
Drug indication
Discovery agent
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION SB-215505 is a potent and subtype-selective 5-HT2B receptor antagonist with pKi values of 8.3, 6.77, 7.66 for 5-HT2B, 5-HT2A, 5-HT2C, respectively[1]. SB-215505 increases wakefulness and motor activity in rats[2].
PRICE 647
DESCRIPTION SB-215505 is a subtype-selective 5-HT2B receptor antagonist that inhibits 5-HT2B, 5-HT2A, and 5-HT2C.SB-215505 can be used to study prostate cancer. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
6
DrugMAP
DMCM4LT
Guide to Pharmacology
190
Mcule NIBR MoA Box Subset
MCULE-4459860807
MedChem Express Bioactive Compound Library
HY-18596
Novartis Chemogenetic Library (NIBR MoA Box)
TargetMol Bioactive Compound Library
T28680
External IDs
15
Properties
(calculated by RDKit )
Molecular Weight
337.1
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
4
Aromatic Ring Count
3
cLogP
4.79
TPSA
45.23
Fraction CSP3
0.16
Chiral centers
0.0
Largest ring
6.0
QED
0.69
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
5-HT2B
5-HT2A
5-HT2C
5-HT Receptor
Member status
member
MOA
5-HT2B Antagonists
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Source data